Eltrombopag is used to stop bleeding episodes in adults and children age 1 year and older, that have persistent immune thrombocytopenic purpura. Eltrombopag is not a treatment for ITP and it will not make your platelet counts normal if you have this condition. Eltrombopag is also used to avoid bleeding in adults with persistent liver disease C who are treated with an interferon. Eltrombopag is additionally used along with other medications to treat serious aplastic anemia in adults and children who are at least 2 years old. Eltrombopag might be used for functions not detailed in this medication guide. Eltrombopag might harm an expected baby. Your physician may sometimes change your dose. Mix the oral suspension powder only with water. You may require regular medical tests to inspect your bone marrow cells or liver function. If the child gains or loses weight, your child's dosage needs may change. It may occupy to 4 weeks prior to the medication avoids major blood loss episodes. If you have any bruising or hemorrhaging episodes after 4 weeks of taking eltrombopag, keep taking eltrombopag as routed and inform your doctor. Tell your medical professional if you stop utilizing any of your liver disease drugs if you take eltrombopag with medicine to deal with chronic hepatitis C. After mixing eltrombopag oral suspension, store the fluid at room temperature and use it within 30 mins. After you quit taking eltrombopag, your risk of blood loss or bruising may be even higher than it was before you started treatment. Avoid the missed out on dose and take your next dosage at the routine time.
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions
** If you believe that content on the Plex is summarised improperly, please, contact us, and we will get rid of it quickly; please, send an email with a brief explanation.
CID | MolecularFormula | MolecularWeight | CanonicalSMILES | IsomericSMILES | InChI | InChIKey | IUPACName | XLogP | ExactMass | MonoisotopicMass | TPSA | Complexity | Charge | HBondDonorCount | HBondAcceptorCount | RotatableBondCount | HeavyAtomCount | IsotopeAtomCount | AtomStereoCount | DefinedAtomStereoCount | UndefinedAtomStereoCount | BondStereoCount | DefinedBondStereoCount | UndefinedBondStereoCount | CovalentUnitCount |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
135449332 | C25H22N4O4 | 442.5 | CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C | CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N=NC3=CC=CC(=C3O)C4=CC(=CC=C4)C(=O)O)C | InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,28,30H,1-3H3,(H,32,33) | SVOQIEJWJCQGDQ-UHFFFAOYSA-N | 3-[3-[[2-(3,4-dimethylphenyl)-5-methyl-3-oxo-1H-pyrazol-4-yl]diazenyl]-2-hydroxyphenyl]benzoic acid | 5.4 | 442.16410520 | 442.16410520 | 115 | 812 | 0 | 3 | 7 | 5 | 33 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Plex Page is a Biology & Health Sciences "Online Knowledge Base," where a machine summarizes all the summaries.